These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

806 related items for PubMed ID: 11965039

  • 1. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, Olson L, Esquenazi V, Miller J.
    Transplantation; 2002 Apr 15; 73(7):1100-6. PubMed ID: 11965039
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
    Bruce DS, Sollinger HW, Humar A, Sutherland DE, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ.
    Transplantation; 2001 Nov 27; 72(10):1637-43. PubMed ID: 11726823
    [Abstract] [Full Text] [Related]

  • 5. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G, Miller A, Burke GW, Gharagozloo H, Rosen A, Roth D, Kupin W, Pinna A, Cespedes M, Esquenazi V, Miller J.
    Transplant Proc; 2001 Nov 27; 33(1-2):1013-4. PubMed ID: 11267169
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G, Burke GW, Suzart K, Vaidya A, Roth D, Kupin W, Mattiazzi A, Rosen A, Esquenazi V, Miller J.
    Transplant Proc; 2003 Mar 27; 35(2):873-4. PubMed ID: 12644172
    [No Abstract] [Full Text] [Related]

  • 7. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J.
    Transplantation; 2005 Aug 27; 80(4):457-65. PubMed ID: 16123718
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
    Abramowicz D, Vanrenterghem Y, Squifflet JP, Kuypers D, Mourad M, Meurisse M, Wissing M.
    Clin Transplant; 2005 Aug 27; 19(4):475-82. PubMed ID: 16008591
    [Abstract] [Full Text] [Related]

  • 10. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J.
    Transplantation; 2008 Jul 15; 86(1):67-74. PubMed ID: 18622280
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients.
    Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, Hudson S, Bynon JS.
    Transplantation; 2000 May 15; 69(9):1867-72. PubMed ID: 10830224
    [Abstract] [Full Text] [Related]

  • 13. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 14. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A.
    Transplantation; 2006 Jul 15; 82(1):62-8. PubMed ID: 16861943
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, Sheiner PA, Kim-Schluger L, Schwartz ME, Miller CM.
    Liver Transpl; 2001 Mar 27; 7(3):220-5. PubMed ID: 11244163
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.